SILO - Silo Pharma Inc. Stock Price, Fair Value and News

$0.45-0.01 (-2.17%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SILO Price Action

Last 30 days

-13.5%

Last 90 days

-25%

Trailing 12 Months

-55.0%

SILO RSI Chart

SILO Valuation

Market Cap

6.0M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

6.98

EV/EBITDA

-0.41

Price/Free Cashflow

-1.25

SILO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SILO Fundamentals

SILO Revenue

Revenue (TTM)

858.3K

Rev. Growth (Yr)

-93.04%

Rev. Growth (Qtr)

-93.98%

SILO Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

-19.55%

Earnings Growth (Qtr)

7.79%

SILO Profitability

Operating Margin

97.08%

EBT Margin

-591.48%

Return on Equity

-101.36%

Return on Assets

-79.52%

Free Cashflow Yield

-80.07%

SILO Investor Care

Shares Dilution (1Y)

196.99%

Diluted EPS (TTM)

-0.93

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	1.2M	1.1M	1.2M	0
2024	1.7M	1.5M	1.4M	1.2M
2023	1.7M	2.0M	1.9M	1.7M
2022	1.3M	1.1M	1.2M	1.5M
2021	1.4M	1.4M	1.5M	1.6M
2020	642.4K	853.8K	1.1M	1.3M
2019	0	0	0	431.0K
2018	0	0	0	0
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Silo Pharma Inc.

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

CEO	Mr. Eric Weisblum
WEBSITE	https://silopharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	3

Silo Pharma Inc. Frequently Asked Questions

What is the ticker symbol for Silo Pharma Inc.? What does SILO stand for in stocks?

SILO is the stock ticker symbol of Silo Pharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silo Pharma Inc. (SILO)?

As of Wed Dec 03 2025, market cap of Silo Pharma Inc. is 5.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILO stock?

You can check SILO's fair value in chart for subscribers.

Is Silo Pharma Inc. a good stock to buy?

The fair value guage provides a quick view whether SILO is over valued or under valued. Whether Silo Pharma Inc. is cheap or expensive depends on the assumptions which impact Silo Pharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILO.

What is Silo Pharma Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SILO's PE ratio (Price to Earnings) is -1.18 and Price to Sales (PS) ratio is 6.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILO PE ratio will change depending on the future growth rate expectations of investors.